Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29191917 | 0.89 | DRD2 (0.42) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL29191918 | 0.89 | DRD2 (0.42) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL28973264 | 0.84 | BTK (0.46) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL4805477 | 0.83 | MAPT (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL23603812 | 0.82 | BTK (0.41) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL29170262 | 0.82 | BTK (0.41) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL25070777 | 0.82 | BTK (0.41) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL28984107 | 0.81 | EPHX1 (0.46) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL28984106 | 0.81 | EPHX1 (0.46) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL5491684 | 0.81 | MAPT (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171567-B1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2025-03-27 | — | — | US | disclosed |
| US-20240374591-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-14 | — | — | US | disclosed |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| US-12103920-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-10-01 | — | — | US | disclosed |
| US-20230242509-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11634407-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-11560371-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103920-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, ESRRA | DRD2 548/4885EPHX1 3920/4885BTK 4267/4885 |
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | DRD2 842/4885EPHX1 3905/4885BTK 4329/4885 |
| US-20240374591-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | DRD2 640/4885EPHX1 3980/4885BTK 4192/4885 |
| US-20230242509-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | DRD2 548/4885EPHX1 3920/4885BTK 4267/4885 |
| US-11634407-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, ESRRA | DRD2 548/4885EPHX1 3920/4885BTK 4267/4885 |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, SHBG | DRD2 596/4885EPHX1 3697/4885BTK 4309/4885 |
| US-11560371-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, SHBG | DRD2 750/4885EPHX1 4045/4885BTK 4344/4885 |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | DRD2 548/4885EPHX1 3920/4885BTK 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.